• 1.

    Wheeler DC, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. Published online August 30, 2020. doi: 10.1093/ndt/gfaa234AstraZeneca

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease. March 30, 2020. https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl J Med. Published online August 29, 2020. doi: 10.1056/NEJMoa2022190

  • 4.

    McMurray J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:19952008. doi: 10.1056/NEJMoa1911303

  • 5.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

SGLT2s Show Promise for Kidney Protection Benefits Seen in Patients with and without Diabetes

By Bridget M. Kuehn
Search for other papers by By Bridget M. Kuehn in
Current site
Google Scholar
Restricted access